Mark Stanley Berger - 18 Feb 2023 Form 4 Insider Report for Genprex, Inc. (GNPX)

Role
Chief Medical Officer
Signature
/s/ Catherine Vaczy as Attorney-in-Fact for Mark Berger
Issuer symbol
GNPX
Transactions as of
18 Feb 2023
Net transactions value
$0
Form type
4
Filing time
22 Feb 2023, 17:35:05 UTC
Previous filing
08 Feb 2022
Next filing
21 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNPX Common Stock Award $0 +245,000 $0.000000 245,000 18 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.